Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cancer Genetics Inc (CGIX)

Cancer Genetics Inc (CGIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,541
  • Shares Outstanding, K 2,100
  • Annual Sales, $ 27,470 K
  • Annual Income, $ -20,370 K
  • 60-Month Beta 2.53
  • Price/Sales 0.28
  • Price/Cash Flow N/A
  • Price/Book 1.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +768,561.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.81 +31.76%
on 01/27/20
5.85 -14.19%
on 02/20/20
+0.59 (+13.32%)
since 01/21/20
3-Month
3.81 +31.76%
on 01/27/20
9.50 -47.16%
on 11/29/19
+0.55 (+12.30%)
since 11/21/19
52-Week
2.00 +150.60%
on 11/19/19
9.88 -49.22%
on 04/09/19
-2.48 (-33.07%)
since 02/21/19

Most Recent Stories

More News
Cancer Genetics Issues Letter to Shareholders

Cancer Genetics, Inc. (Nasdaq: CGIX) ("Cancer Genetics" or the "Company"), a leader in drug discovery and preclinical oncology and immuno-oncology services, today published a letter to shareholders from...

CGIX : 5.02 (-7.72%)
Delcath Systems Elects Seasoned Finance and Capital Markets Executive Elizabeth Czerepak to its Board of Directors

Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that Elizabeth Czerepak, a financial executive and board...

ALT : 1.76 (-0.56%)
CGIX : 5.02 (-7.72%)
DCTH : 12.0000 (+25.65%)
Breakthrough Study Makes Cancer Detection Possible With a Simple Blood Test; Introduces a New Systemic Hallmark of Cancer

A new study by scientists from India, USA, and UK has presented clinical evidence for an innovative test that can detect clusters of cancer cells in the blood of asymptomatic individuals as a non-invasive...

CGIX : 5.02 (-7.72%)
Breakthrough Study Makes Cancer Detection Possible With a Simple Blood Test; Introduces a New Systemic Hallmark of Cancer

- The new study by Datar Cancer Genetics [https://datarpgx.com/] has used a revolutionary new method that detects clusters of tumor cells circulating in the bloodstream and helps in early detection of...

CGIX : 5.02 (-7.72%)
Cancer Genetics Reports Third Quarter 2019 Financial Results and Provides Strategic Business Update

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced strategic, financial and operating results for the third quarter...

CGIX : 5.02 (-7.72%)
Cancer Genetics, Inc. Announces Strategic Transactions

Note Payment Received from Interpace Diagnostics Group, Inc.

CGIX : 5.02 (-7.72%)
IDXG : 10.55 (+2.63%)
Cancer Genetics Announces 1-for-30 Reverse Stock Split

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced that it will effect a 1-for-30 reverse stock split of its outstanding...

CGIX : 5.02 (-7.72%)
Interpace Announces Closing of $13 Million Second Tranche Acquisition Financing from Ampersand Capital Partners

Interpace Diagnostics Group, Inc. (IDXG) announced today that it has closed on a $13 million Convertible Preferred Stock investment by Ampersand Capital Partners (Ampersand). This investment constitutes...

CGIX : 5.02 (-7.72%)
IDXG : 10.55 (+2.63%)
Datar Cancer Genetics Announces Positive Results With 42.9% Objective Response Rate, and 90.5% Disease Control Rate in Heavily Pre-treated Patients With Ultra-personalised Pan-cancer Treatment Protocol in the RESILIENT Trial

LONDON, MUMBAI, India and BAYREUTH, Germany, Oct. 9, 2019 /PRNewswire/ --

CGIX : 5.02 (-7.72%)
Datar Cancer Genetics Announces Positive Results With 42.9% Objective Response Rate, and 90.5% Disease Control Rate in Heavily Pre-treated Patients With Ultra-personalised Pan-cancer Treatment Protocol in the RESILIENT Trial

https://mma.prnewswire.com/media/1008171/Datar_Cancer_Genetics_Limited_Logo.jpg

CGIX : 5.02 (-7.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CGIX with:

Business Summary

Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company's tests target cancers, including hematological, urogenital, and HPV-associated...

See More

Key Turning Points

2nd Resistance Point 5.78
1st Resistance Point 5.40
Last Price 5.02
1st Support Level 4.68
2nd Support Level 4.34

See More

52-Week High 9.88
Fibonacci 61.8% 6.87
Fibonacci 50% 5.94
Last Price 5.02
Fibonacci 38.2% 5.01
52-Week Low 2.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar